Cover Image

Assessment of lipoprotein-associated phospholipase a2 in coronary artery disease patients of north India

Brijesh Rathore*, Sumit Thakur, Kalpana Jaggi, Ritu Karoli, Abhishek Mathur, Farzana Mahdi

Abstract


Lipoprotein associated phospholipase A2 (Lp-PLA2) is an inflammatory biomarker which play an important role in the pathophysiology of coronary artery disease (CAD). Lp-PLA2 is produced by inflammatory cells like monocytes, macrophage etc. it hydrolyses platelet activating factor and oxidatively fragmented phospholipids. It is an emerging risk factor for CAD, because of its high vascular specificity and direct relation with plaque instability and rupture. Several reports reveal that plasma Lp-PLA2 is a good biomarker of vascular inflammation, atherosclerotic vulnerability and future cardiovascular events. The correlation between Lp-PLA2 and CAD remains poorly investigated in north Indian population. This study is aimed to investigate the Lp-PLA2 levels as a predictor of CAD. Study was conducted with One hundred fifty CAD patients and One hundred fifty normal healthy subjects.  Serum Lp-PLA2 level estimation reveal that CAD patients bears significantly elevated circulatory Lp-PLA2 levels in comparison to normal healthy population. The increase in Lp-PLA2 levels was found irrespective of sex i.e., male and female. We also observed a non-significant change in Lp-PLA2 levels among CAD male and female patients. The study suggests that Lp-PLA2 may be proatherogenic and contribute to atherogenicity and incidence of cardiovascular disease. The stimulated activity of this enzyme may predict CAD patients without known CAD, independent of heart disease risk factors. We can conclude that there is a positive correlation between Lp-PLA2 and risk of CAD events and hence Lp-PLA2 can be considered as a risk associated inflammatory marker for CAD, in north India population.

Keywords


Lp-PLA2; Coronary artery disease; risk factor; Biomarker; north India.

Full Text:

PDF

References


Libby P, Current concepts of the pathogenesis of acute coronary syndromes, Circulation, 2001, 104, 365-372.

Ross R, Atherosclerosis-an inflammatory disease, N Engl J Med, 1999, 340, 115-126.

Elkind MSV, Sciacca R, Boden-Albala B, Rundek T, Paik MC, Sacco RL, Relative elevation in leukocyte count predicts first cerebral infarction, Neurology, 2005, 64, 2121-2125.

Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB, Prediction of coronary heart disease using risk factor categories, Circulation, 1998, 97, 1837-1847.

Tjoelker LW, Eberhart C, Unger J, Plasma platelet activating factor acetylhydrolase is a secreted Phospholipase A2 with a catalytic triad, J Biol Chem, 1995, 270, 25481-25487.

Gazi I, Lourida ES, Filippatos T, Tsimihodimos V, Elisaf M, Tselepis AD, Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma, Clin Chem, 2005, 51, 2264-2273.

Takahashi M, Okazaki H, Ogata Y, Takeuchi K, Ikeda U, Shimada K, Lysophosphatidylcholine induces apoptosis in human endothelial cells through a p38 mitogen activated protein kinase-dependent mechanism, Atherosclerosis, 2009, 161, 387-394.

Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, Lp-PLA2 Studies Collaboration, Lipoprotein associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studie, Lancet, 2010, 375, 1536-1544.

Davidson MH, Corson MA, Alberts MJ, Anderson JL, Gorelick PB, Jones PH, Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines, Am J Cardiol, 2008, 101, 51F-57F.

Gardner AA, Reichert EC, Alexander TS, Topham MK, Stafforini DM, Novel mechanism for regulation of plasma platelet-activating factor acetylhydrolase expression in mammalian cells, Biochem J, 2010, 13, 428(2), 269-279.

Suchindran S, Rivedal D, Guyton JR, Milledge T, Gao X, Benjamin A, Rowell J, Ginsburg GS, McCarthy JJ, Genome-wide association study of Lp-PLA(2) activity and mass in the Framingham Heart Study, PLoS Genet, 2010, 29, 6(4), e1000928.

Wang WY, Li J, Yang D, Xu W, Zha RP, Wang YP, OxLDL stimulates lipoprotein-associated phospholipase A2 expression in THP-1 monocytes via PI3K and p38 MAPK pathways, Cardiovasc Res, 2010, 1, 85(4), 845-852.

Kim JY, Hyun YJ, Jang Y, Lee BK, Chae JS, Kim SE, Yeo HY, Jeong TS, Jeon DW, Lee JH, Lipoprotein-associated phospholipase A2 activity is associated with coronary artery disease and markers of oxidative stress: a case-control study, Am J Clin Nutr, 2008, 88(3), 630-637.

Raichlin E, McConnell JP, Bae JH, Kremers WK, Lerman A, Frantz RP, Lipoprotein-associated phospholipase A2 predicts progression of cardiac allograft vasculopathy and increased risk of cardiovascular events in heart transplant patients, Transplantation, 2008, 15, 85(7), 963-968.

Gregson J, Stirnadel-Farrant HA, Doobaree IU, Koro C, Variation of lipoprotein associated phospholipase A2 across demographic characteristics and cardiovascular risk factors: a systematic review of the literature, Atherosclerosis, 2012, 22, 11-21.

Ballantyne CM, Hoogeveen RC, Bang H, Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study, Arch Intern Med, 2005, 165, 2479-2484.

Ballantyne CM, Hoogeveen RC, Bang H, Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study, Circulation, 2004, 109, 837-842.

Hirschler V, Is lipoprotein-associated phospholipase A2 correlated with cardiovascular risk in European women, Indian J Med Res, 2013, 138, 832-833.

Kizer JR, Umans JG, Zhu J, Devereux RB, Wolfert RL, Lee ET, Lipoprotein-associated phospholipase A(2) mass and activity and risk of cardiovascular disease in a population with high prevalences of obesity and diabetes: the Strong Heart Study, Diabetes Care, 2012, 35, 840-847.




DOI: http://dx.doi.org/10.21746/ijbio.2014.09.005

Refbacks

  • There are currently no refbacks.




Copyright (c) 2014 International Journal of Bioassays

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

International Journal of Bioassays is a member of the Publishers International Linking Association, Inc. (PILA), CROSSREF and CROSSMARK (USA). Digital Object Identifier (DOI) will be assigned to all its published content.